CMA and its regulatory members have, over the last few years been progressing work in relation to the Permitted Indications Project. Recent work has included revising a list of current indications that the TGA considered as including wording that could arguably be termed a “restricted representation”. On the 10 October, CMA provided TGA with a detailed response to a range of proposed “re-worded” indications and “priority removal” of indications which were proposed to be archived.

A summary of recent changes in relation to permitted indications in listed medicines is provided in the attached alert, click here to read more.